Pushing the Limits of Bioanalysis
Overcoming Selectivity Challenges in Medical Device Studies
In this report, Veloxity Labs details how we overcame critical selectivity challenges during a medical device study requiring ultra-sensitive bioanalysis in human plasma. By developing and validating a method with a 30 pg/mL LLOQ — while navigating unexpected interference — we optimized sample prep, chromatography and mobile phases to reduce analysis time by 70%. The result: a robust, cost-effective solution ready for clinical development. Download the full report to see how Veloxity’s expertise in bioanalytical method development supports success in pharma and biotech.